Prostatic Cancer: An Age-Old Problem

  • John T. Isaacs
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 330)


During this year there will be approximately 30 thousand deaths due to prostatic cancer in the United States (1). This mortality rate makes prostatic cancer the second commonest fatal tumor in males of all ages in America (1). Besides a high annual mortality rate, prostatic cancer is now the most commonly diagnosed malignancy in males of all ages in the United States (1). These high annual incidence rates translate into the human reality that one of every 11 American white male will eventually develop clinical prostatic cancer during their lifetime (2). Rates for American black males are even higher such that the lifetime risk for cancer is one out of every 10 (3). In addition, the annual incidence rate of clinical prostatic cancer has increased steadily since 1930’s to the present time (4).


Prostatic Cancer Programme Cell Death Metastatic Prostatic Cancer Androgen Ablation Androgen Ablation Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boring, C., Squires, T. and Tong, T. Cancer Statistics — Cancer Journal for Clinicians 42:19–38, 1992.CrossRefGoogle Scholar
  2. 2.
    Seidman, H., Mushinski, M. H., Gelb, S. K. and Silverberg, E. Probabilities of eventually developing or dying of cancer: United States. Cancer Journal for Clinicians 35:36–56, 1985.CrossRefGoogle Scholar
  3. 3.
    Mettlin, G. Epidemiology of prostate cancer in different population groups. Clinics in Oncology 2:287–300, 1983.Google Scholar
  4. 4.
    Devesa, S. S. and Silverman, D. T. Cancer incidence and morbidity trends in the United States: 1935-1947. J. Natl. Cancer Inst. 60:545–571, 1978.PubMedGoogle Scholar
  5. 5.
    Carter, H. B. and Isaacs, J. T. Experimental and theoretical basic for hormonal treatment of prostatic cancer. Seminars in Urology 4:262–268, 1988.Google Scholar
  6. 6.
    U.S. Bureau of the Census, Statistical Abstract of the United States 1989 (109th edition) Washington, DC, 1989.Google Scholar
  7. 7.
    Horm, J. and Sondik, E. Person-Years of life lost due to cancer in the United States 1970 and 1984. Am. J. Public Health 79:1490–1493, 1989.PubMedCrossRefGoogle Scholar
  8. 8.
    Carter, H. and Coffey, D. Prostate cancer: The magnitude of the problem in the United States. In Coffey, D., Resnick, M., Dorr, F. et. al (eds): A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Plenum Press, New York, Pp. 1–9, 1988.CrossRefGoogle Scholar
  9. 9.
    Carter, H. B., Piantadosi, S. and Isaacs, J. T. Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol. 143:742–746, 1990.PubMedGoogle Scholar
  10. 10.
    Dhom, G. Classification and grading of prostatic carcinoma. Recent Results Cancer Res 60:14–26, 1977.PubMedCrossRefGoogle Scholar
  11. 11.
    Hohbach, C. and Dhom, G. Pathology of prostatic cancer. Scand. J. Urol Nephrol 55:37, 1980.Google Scholar
  12. 12.
    Watanabe, H., Ohe, H., Inaba, T., Itakura, Y., Saitoh, M. and Nakao, M. A mobile mass screening unit for prostatic disease. Prostate 5:559, 1984.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang, P., Cheng, S., Zhou, Y., He, A., Hu, J., Huang, S. General survey to detect prostatic disease in 1,165 aged males over 60. Chinese J. Geriat. 3:99, 1984.Google Scholar
  14. 14.
    Miller, G. J. Diagnosis of stage A prostate cancer in the People’s Republic of China. In: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Edited by D. S. Coffey, M. I. Resnick, F. A. Door, and J. P. Karr. Plenum Press, New York. Pp. 17–24, 1988.CrossRefGoogle Scholar
  15. 15.
    Dunn, J. E. Cancer epidemiology in populations of the United States — with emphasis on Hawaii and California — and Japan. Cancer Res 35:3240, 1975.PubMedGoogle Scholar
  16. 16.
    Haenszel, W. and Kurihara, M. Studies on Japanese migrants. I. Mortality for cancer and other diseases among Japanese in the United States. J. Natl Cancer Inst. 40; 43, 1968.PubMedGoogle Scholar
  17. 17.
    Akazaki, K. and Stemmerman, G. N. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J. Natl Cancer Inst. 50:1137, 1973.PubMedGoogle Scholar
  18. 18.
    Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Seminars in Oncology 15:371–389, 1988.PubMedGoogle Scholar
  19. 19.
    Scott, W.W., Menon, M. and Walsh, P.C. Hormonal therapy of prostatic cancer. Cancer 45:1929–1936, 1980.PubMedGoogle Scholar
  20. 20.
    Schulze, H., Isaacs J.T. and Coffey, D. S. A critical review of the concept of total androgen ablation in the treatment of prostatic cancer. IN Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds). Prostate Cancer Part A: Research Endocrine Treatment, and Histopathology. Progress in Clinical and Biological Research Vol. 243A: pp. 1–19. Alan R. Liss, Inc., New York, 1987.Google Scholar
  21. 21.
    Smith, J. A., Eyse, H.J., Roberts, T. S. and Middleton, R. G. Transphenoidal hypophysectomy in the management of carcinoma of the prostate. Cancer 53:2385–2387, 1984.PubMedCrossRefGoogle Scholar
  22. 22.
    Menon, M. and Walsh, P. C. Hormonal therapy for prostatic cancer. In Murphy GP (ed). Prostatic Cancer. Littleton, Mass, PSG Publ. Co., pp 175–200, 1979.Google Scholar
  23. 23.
    Lepor, H., Ross, A. and Walsh, P. C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J. Urol. 128:335–340, 1982.PubMedGoogle Scholar
  24. 24.
    Prout, G. R., Leiman, B., Daly, J.J., Macloughlin, R. A., Griffin, P. P., Young, H. H. Endocrine changes after diethylstilbestrol therapy. Urology 7:148–155, 1976.PubMedCrossRefGoogle Scholar
  25. 25.
    Sinha, A. A., Blackhard, C. E., Seal, U. S. A critical analysis of tumor morphology and hormone treatment in the untreated and estrogen treated responsive and refractory human prostatic carcinoma. Cancer 40:2836–2850, 1977.PubMedCrossRefGoogle Scholar
  26. 26.
    Isaacs, J. T. and Coffey, D. S. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res 41:5070–5075, 1981.PubMedGoogle Scholar
  27. 27.
    Isaacs, J. T. Cellular factors in the development of resistance to hormonal therapy. In Bruchovsky, N. and Goldie, J. (eds). Drug and Hormone Resistance in Neoplasia. Vol. 1. CRC Press, Boca Raton, Inc. Pp 139-156, 1982.Google Scholar
  28. 28.
    Ellis, W. J. and Isaacs, J. T. Effectiveness of complete vs partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic carcinoma. Cancer Res 45:6041–6050, 1985.PubMedGoogle Scholar
  29. 29.
    Redding, T. W. and Schally, A. V. Investigation of the combination of the agonist D-Trp-6-LHRH and the antiandrogen flutamide on the treatment of Dunning R-3327 H prostatic cancer model. The Prostate 6:219–232, 1985.PubMedCrossRefGoogle Scholar
  30. 30.
    Kung, T.T., Mingo, G. G., Siegel, M. I., Watnick, A. S. Effect of adrenalectomy, flutamide and leuprolide on the growth of the Dunning R-3327 prostatic carcinomas. The Prostate 12:357–364, 1988.PubMedCrossRefGoogle Scholar
  31. 31.
    Isaacs, J. T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate 5:1–18, 1984.PubMedCrossRefGoogle Scholar
  32. 32.
    Isaacs, J. T. Relationship between tumor size and curability of prostate cancer by combined chemohormonal therapy. Cancer Res 49:6290–6294, 1989.PubMedGoogle Scholar
  33. 33.
    Schulze, H., Isaacs, J. and Senge, T. Inability of complete androgen blockage to increase survival of patients with advanced prostatic cancer as compared to standard hormone therapy. J. Urol. 137:909–914, 1987.PubMedGoogle Scholar
  34. 34.
    Helpap, B., Steins, R. and Bruhl, P. Autoradiographic in vitro investigations of prostatic tissue with C-14 and H-3 thymidine double labelling method. Beitr Pathol. Anal. Allgem. Path. 151:65–72, 1974.CrossRefGoogle Scholar
  35. 35.
    Meyer, J. S., Sufrin, G. and Martin, S. A. S. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol. 128:1353–1356, 1982.PubMedGoogle Scholar
  36. 36.
    Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate 5:545–558, 1984.PubMedCrossRefGoogle Scholar
  37. 37.
    Kyprianou, N. and Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552–562, 1988.PubMedCrossRefGoogle Scholar
  38. 38.
    Wyllie, A. H., Kerr, J. F.R. and Currie. A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:251–306, 1986.CrossRefGoogle Scholar
  39. 39.
    Kerr, J. F. R., Wyllie, A. H. and Currie, A. R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Brit. J. Cancer 26:239–257, 1972.PubMedCrossRefGoogle Scholar
  40. 40.
    Bowen, I. D. and Lockshin, R. A. Cell Death in Biology and Pathology. London: Chapman and Hill, 1981.CrossRefGoogle Scholar
  41. 41.
    Wyllie, A. H. Glucocorticoid induces in thymocytes a nuclease-like activity associated with the chromatin condensation of apoptosis. Nature 284:555–556, 1980.PubMedCrossRefGoogle Scholar
  42. 42.
    Umansky, S. R., Korol, B. A. and Nelipovich, P. A. In vivo DNA degradation in thymocytes of-irradiated or hydrocortisone-treated rats. Biochim. Biophys. Acta 655:9–17, 1981.PubMedCrossRefGoogle Scholar
  43. 43.
    Wyllie, A. H., Kerr, J. F. R, Macaskill, I. A. M. and Currie, A. R. Adrenocortical cell deletion: the role of ACTH. J. Pathol. 111:85–94, 1973.PubMedCrossRefGoogle Scholar
  44. 44.
    Cohen, J. J. and Duke, R. C. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol. 132:38–42, 1984.PubMedGoogle Scholar
  45. 45.
    Wyllie, A. H., Morris, R. G., Smith, A. L., Dunlop, D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol. 142:67–77, 1984.PubMedCrossRefGoogle Scholar
  46. 46.
    Compton, M. M. and Cidlowski, J. A. Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology 118:38–45, 1986.PubMedCrossRefGoogle Scholar
  47. 47.
    Kyprianou, N., English, H. F. and Isaacs, J. T. Activation of a Ca+2-Mg+2-dependent endonuclease as an early event in castration-induced prostatic cell death. The Prostate 13:103–118, 1988.PubMedCrossRefGoogle Scholar
  48. 48.
    English, H. F., Kyprianou, N. and Isaacs, J. T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. The Prostate 15:233–250, 1989.PubMedCrossRefGoogle Scholar
  49. 49.
    Kerr, J. F.R. and Searle, J. Deletion of cells by apoptosis during castrationinduced involution of the rat prostate. Virchow Archiv B 13:87–102, 1973.Google Scholar
  50. 50.
    Lesser, B. and Bruchovsky, N. The effects of testosterone, 5-dihydrotestosterone and adenosine 3’,5’-monophosphate on cell proliferation and differentiation in rat prostate. Biochim. Biophys. Acta 308:426–437, 1973.PubMedCrossRefGoogle Scholar
  51. 51.
    Lee, C. Physiology of castration-induced regression of the rat prostate. Prog. Clin. Biol. Res. 75A:145–159, 1982.Google Scholar
  52. 52.
    Sanford, M. L., Searle, J. W. and Kerr, J. F. R. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology 16:406–410, 1984.CrossRefGoogle Scholar
  53. 53.
    Stanisic, T., Sadlowski, R., Lee, C., Grayhack, J. T. Partial inhibition of castrationinduced ventral prostate regression with actinomycin D and cycloheximide. Invest. Urol. 16:19–22, 1978.PubMedGoogle Scholar
  54. 54.
    Lee, C. and Sensibar, J. A. Protein of the rat prostate: synthesis of new proteins in the ventral lobe during castration-induced regression. J. Urol. 138:903–908, 1985.Google Scholar
  55. 55.
    Salzman, A. G., Hiipakka, R. A., Chang, C., Liao, S. Androgen repression of the production of a 29 kilodalton protein and its mRNA in the rat ventral prostate. J. Biol. Chem. 262:432–437, 1987.Google Scholar
  56. 56.
    Montpetit, M. L., Lawless, K. R. and Tenniswood, M. Androgen repressed messages in the rat ventral prostate. The Prostate 8:25–36, 1986.PubMedCrossRefGoogle Scholar
  57. 57.
    Buttyan, R., Zaker, Z., Lockshin, R. and Wolgemuth, D. Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol. Endocrinol. 2:650–657, 1988.PubMedCrossRefGoogle Scholar
  58. 58.
    Kyprianou, N. and Isaacs, J. T. Expression of transforming growth factor-B in the rat ventral prostate during castration-induced programmed cell death. Mol. Endocrinol. 3:1515–1522, 1989.PubMedCrossRefGoogle Scholar
  59. 59.
    Connor, J., Sawdzuk, I. S., Benson, M. C., Tomashersky, P., OTool, K. M., Olsson, C. A. and Buttyan, R. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. The Prostate 13:119–130, 1988.PubMedCrossRefGoogle Scholar
  60. 60.
    Viskochil, D. H., Perry, S. T., Lea, D. A., Stafford, D. W., Wilson, E. M., French, E S. Isolation of two genomic sequences encoding the mr ∼ 1400 subunit of rat prostatein. J. Biol. Chem. 258:8861–8866, 1983.PubMedGoogle Scholar
  61. 61.
    Martikainen, P. and Isaacs, J. T. An organ culture system for the study of programed cell death in the rat ventral prostate. Endocrinology 127:1258–1267, 1990.Google Scholar
  62. 62.
    Martikainen, P. and Isaacs, J. T. Role of calcium in the programmed death of rat prostatic glandular cells. The Prostate 17:175–187, 1991.CrossRefGoogle Scholar
  63. 63.
    Kyprianou, N., English, H., and Isaacs., J. T. Programmed cell death during regression of PC-82 human prostatic cancer. Cancer Res. 50:3748–3753, 1990.PubMedGoogle Scholar
  64. 64.
    van Steenbrugge, G. J., Groen, M., Romijn, J. C. and Schroder. E Biological effects of hormonal treatment regimens on the transplantable human prostate tumor line (PC-82). J. Urol. 131:812–817, 1984.PubMedGoogle Scholar
  65. 65.
    Kyprianou, N. and Isaacs, J. T. Thymine-less death in androgen-independent prostatic cancer cells. Biochem. Biophys. Res. Comm. 165:73–81, 1989.PubMedCrossRefGoogle Scholar
  66. 66.
    Tucker, R. W., Meade-Cobun, K., Loats, H. Measurement of free intracellular calcium (Ca) in fibroblasts. Digital image analysis of Fura 2 fluorescence. In Fiskum, G. (ed), Plenum Publ. Corp. Pp 239-248, 1989.Google Scholar
  67. 67.
    Martikainen, P., Kyprianou, N., Tucker, R. W. and Isaacs, J. R. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Research 51:4693–4700, 1991.PubMedGoogle Scholar
  68. 68.
    Bettuzzi, S., HYiipakka, R. A., Gilna, P., Liao, S. Identification of an androgenrepressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem. J. 257:293–296, 1989.PubMedGoogle Scholar
  69. 69.
    Sylvester, S. R., Skinner, M. K. and Griswold, M. D. A sulfated glycoprotein synthesized by Sertoli cell and by epididymal cells is a component of the sperm membrane, Biol. Reproduc. 31:1087–1101, 1984.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • John T. Isaacs
    • 1
  1. 1.Johns Hopkins Oncology Center and the Department of UrologyThe Johns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations